Sanofi has announced the launch of AVAXIM Junior in the UK, a travel vaccination for children to protect against the hepatitis A virus.
AVAXIM Junior is an inactive hepatitis A vaccine indicated for use in children from the age of 12 months, up to and including 15 years old.
Rebecca Catterick, UK and Ireland Sanofi vaccines general manager, commented that hepatitis A was ‘one of the most prevalent travel-related vaccine-preventable diseases’.
‘The availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas,’ she added.
Hepatitis A is caused by the hepatitis A virus and is the most common form of viral hepatitis, as well as the third most common vaccine-preventable infection among travellers.
It is primarily transmitted through contaminated food and water or by direct contact with an infectious person, and has a higher prevalence in developing countries with poor sanitary conditions and hygiene practices, according to the World Health Organization.
Read how Sehul Patel, owner and superintendent pharmacist at Coopers Pharmacy in Sutton, Surrey, maximises his travel health clinic.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.